Some batches of synthetic cannabinoids have been contaminated with brodifacoum, a long-acting vitamin K antagonist (superwarfarin) used as a rodenticide. A person exposed to affected cannabinoid will develop a severe coagulopathy.
Major criteria:
(1) prothrombin time >= 14.8 seconds or INR >= 1.3, consistent with a vitamin K dependent coagulation factor deficiency
(2) exposure to a synthetic cannabinoid within the past 30 days
Minor criteria:
(1) active bleeding
(2) exposure to synthetic cannabinoid obtained from a person with known superwarfarin poisoning
(3) presence of superwarfarin on an anticoagulant poisoning panel
Diagnosis of synthetic cannabinoid-associated coagulopathy: both major and >= 1 minor criteria
If a patient is being treated with an anticoagulant, then the diagnosis requires:
(1) exclusion of overdose with that anticoagulant
(2) identifying a superwarfarin on an anticoagulant poisoning panel
To read more or access our algorithms and calculators, please log in or register.
